|
1
|
Brandt CS, Baratin M, Yi EC, Kennedy J,
Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et
al: The B7 family member B7-H6 is a tumor cell ligand for the
activating natural killer cell receptor NKp30 in humans. J Exp Med.
206:1495–1503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu X, Narni-Mancinelli E, Cantoni C, Li Y,
Guia S, Gauthier L, Chen Q, Moretta A, Vély F, Eisenstein E, et al:
Structural insights into the inhibitory mechanism of an Antibody
against B7-H6, a stress-induced cellular ligand for the natural
killer cell receptor NKp30. J Mol Biol. 428:4457–4466. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pesce S, Tabellini G, Cantoni C, Patrizi
O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini
S and Marcenaro E: B7-H6-mediated downregulation of NKp30 in NK
cells contributes to ovarian carcinoma immune escape.
Oncoimmunology. 4:e10012242015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vivier E, Tomasello E, Baratin M, Walzer T
and Ugolini S: Functions of natural killer cells. Nat Immunol.
9:503–510. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bretscher P and Cohn M: A theory of
self-nonself discrimination. Science. 169:1042–1049. 1970.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flies DB and Chen L: The new B7s: Playing
a pivotal role in tumor immunity. J Immunother. 30:251–260. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hurwitz AA, Kwon ED and van Elsas A:
Costimulatory wars: The tumor menace. Curr Opin Immunol.
12:589–596. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahoney KM and Atkins MB: Prognostic and
predictive markers for the new immunotherapies. Oncology (Williston
Park). 28 Suppl 3:S39–S48. 2016.
|
|
9
|
Mahoney KM, Freeman GJ and McDermott DF:
The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in
melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ceeraz S, Nowak EC and Noelle RJ: B7
family checkpoint regulators in immune regulation and disease.
Trends Immunol. 34:556–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matta J, Baratin M, Chiche L, Forel JM,
Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L,
Chaussabel D, et al: Induction of B7-H6, a ligand for the natural
killer cell-activating receptor NKp30, in inflammatory conditions.
Blood. 122:394–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Zhang G, Qin Y, Bai R and Huang
J: B7-H6 expression in non-small cell lung cancers. Int J Clin Exp
Pathol. 7:6936–6942. 2014.PubMed/NCBI
|
|
13
|
Chen XJ, Shen J, Zhang GB and Chen WC:
B7-H6 protein expression has no prognostic significance in human
gastric carcinoma. Pathol Oncol Res. 20:203–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Xu Y, Chen L, Xu B, Wu C and Jiang
J: B7-H6 expression correlates with cancer progression and
patient's survival in human ovarian cancer. Int J Clin Exp Pathol.
8:9428–9433. 2015.PubMed/NCBI
|
|
15
|
Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang
J and Wu C: B7-H1 expression associates with tumor invasion and
predicts patient's survival in human esophageal cancer. Int J Clin
Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI
|
|
16
|
Seliger B and Quandt D: The expression,
function, and clinical relevance of B7 family members in cancer.
Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J
and Zhang X: T-cell-mediated tumor immune surveillance and
expression of B7 co-inhibitory molecules in cancers of the upper
gastrointestinal tract. Immunol Res. 50:269–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity and immune correlates
of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaifu T, Escalière B, Gastinel LN, Vivier
E and Baratin M: B7-H6/NKp30 interaction: A mechanism of alerting
NK cells against tumors. Cell Mol Life Sci. 68:3531–3539. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo JG, Guo CC, He ZQ, Liu ZG, Wang Y and
Mou YG: Clinical significance of B7-H6 protein expression in
astrocytoma. Onco Targets Ther. 9:3291–3297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fiegler N, Textor S, Arnold A, Rölle A,
Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M and Cerwenka A:
Downregulation of the activating NKp30 ligand B7-H6 by HDAC
inhibitors impairs tumor cell recognition by NK cells. Blood.
122:684–693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Joyce MG, Tran P, Zhuravleva MA, Jaw J,
Colonna M and Sun PD: Crystal structure of human natural
cytotoxicity receptor NKp30 and identification of its ligand
binding site. Proc Natl Acad Sci USA. 108:pp. 6223–6228. 2011;
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
von Strandmann E Pogge, Simhadri VR, von
Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B,
Simhadri VL, Borchmann P, et al: Human leukocyte
antigen-B-associated transcript 3 is released from tumor cells and
engages the NKp30 receptor on natural killer cells. Immunity.
27:965–974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sasaki T, Gan EC, Wakeham A, Kornbluth S,
Mak TW and Okada H: HLA-B-associated transcript 3 (Bat3)/Scythe is
essential for p300-mediated acetylation of p53. Genes Dev.
21:848–861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Correia DV, Fogli M, Hudspeth K, da Silva
MG, Mavilio D and Silva-Santos B: Differentiation of human
peripheral blood Vδ11+ T cells expressing the natural cytotoxicity
receptor NKp30 for recognition of lymphoid leukemia cells. Blood.
118:992–1001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delahaye NF, Rusakiewicz S, Martins I,
Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro
M, et al: Alternatively spliced NKp30 isoforms affect the prognosis
of gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schlecker E, Fiegler N, Arnold A, Altevogt
P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann
EP, Textor S and Cerwenka A: Metalloprotease-mediated tumor cell
shedding of B7-H6, the ligand of the natural killer cell-activating
receptor NKp30. Cancer Res. 74:3429–3440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kellner C, Maurer T, Hallack D, Repp R,
van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M and
Peipp M: Mimicking an induced self phenotype by coating lymphomas
with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J
Immunol. 189:5037–5046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Semeraro M, Rusakiewicz S, Minard-Colin V,
Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C,
Ponzoni M, et al: Clinical impact of the NKp30/B7-H6 axis in
high-risk neuroblastoma patients. Sci Transl Med. 7:283ra2552015.
View Article : Google Scholar
|
